{
  "id": 6328051,
  "title": "Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapy",
  "url": "https://urgent.news/2026/09/08/roivant-surges-on-exceptional-results-bristol-myers-touts-first-of",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-08T18:41:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/roivant-astrazeneca-etcamah-GPRC5D-pharvaris-inhibrx/829763/"
  },
  "original_language": "en",
  "account": null,
  "summary": "One analyst views Roivant’s pulmonary hypertension drug as a future $10 billion-plus seller. Elsewhere, AstraZeneca overcame a negative advisory committee vote and Pharvaris claimed success in a key study.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Endpoints News",
        "title": "Bristol Myers claims Phase 2 success for GPRC5D-directed CAR-T",
        "url": "https://urgent.news/2026/09/08/bristol-myers-claims-phase-2-success-for-gprc5d-directed-car-t",
        "published": "2026-09-08T14:08:51.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}